These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 6734040

  • 1. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L.
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [Abstract] [Full Text] [Related]

  • 2. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G.
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN, Ezzo DC.
    Am J Health Syst Pharm; 2009 Nov 15; 66(22):2024-6. PubMed ID: 19890085
    [Abstract] [Full Text] [Related]

  • 5. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S, Shapira S, Zilbiger A, Ribak J.
    Aviat Space Environ Med; 1984 Nov 15; 55(11):1051-4. PubMed ID: 6508687
    [Abstract] [Full Text] [Related]

  • 6. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy].
    Becker G, Goossens H, Seemann K, Souchon F, Weitz T.
    Dtsch Med Wochenschr; 1984 Dec 07; 109(49):1881-5. PubMed ID: 6499689
    [Abstract] [Full Text] [Related]

  • 7. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME, Royal JW, Shaw JE, Schmitt LG.
    Aviat Space Environ Med; 1979 Nov 07; 50(11):1108-11. PubMed ID: 393242
    [Abstract] [Full Text] [Related]

  • 8. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL, Kohl RL, Reschke MF, Degioanni J, Cintron-Trevino NM.
    Aviat Space Environ Med; 1983 Nov 07; 54(11):994-1000. PubMed ID: 6651736
    [Abstract] [Full Text] [Related]

  • 9. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z, Shupak A, Gordon CR.
    Clin Pharmacokinet; 2006 Nov 07; 45(6):543-66. PubMed ID: 16719539
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG, Phillips JB, Lojewski RA, Wang Z, Boyd JL, Putcha L.
    Aviat Space Environ Med; 2010 Apr 07; 81(4):405-12. PubMed ID: 20377145
    [Abstract] [Full Text] [Related]

  • 12. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A, Gordon CR, Spitzer O, Mendelowitz N, Melamed Y.
    Pharmatherapeutica; 1989 Apr 07; 5(6):365-70. PubMed ID: 2594820
    [Abstract] [Full Text] [Related]

  • 13. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
    Pingree BJ, Pethybridge RJ.
    Aviat Space Environ Med; 1994 Jul 07; 65(7):597-605. PubMed ID: 7945125
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Side effects of some antimotion sickness drugs as measured by psychomotor test and questionnaires.
    Kennedy RE, Wood CD, Graybiel A, McDonough RB.
    Aerosp Med; 1966 Apr 07; 37(4):408-11. PubMed ID: 5954449
    [No Abstract] [Full Text] [Related]

  • 18. Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness.
    Dornhoffer J, Chelonis JJ, Blake D.
    Otol Neurotol; 2004 Sep 07; 25(5):740-5. PubMed ID: 15354005
    [Abstract] [Full Text] [Related]

  • 19. [Transdermally applied scopolamine for continuous prevention of motion sickness. Revival of a 150-year-old method].
    Becker G.
    Schweiz Rundsch Med Prax; 1985 Mar 12; 74(11):271-6. PubMed ID: 3887535
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.